Tags

Type your tag names separated by a space and hit enter

[Development of bisphosphonates].
Nihon Rinsho. 2003 Feb; 61(2):219-25.NR

Abstract

Bisphosphonates (BPs), antiresorptive agents, have been established as first line drugs for treatment of osteoporosis and widely used all over the worlds. In Japan alendronate and risedronate, newer generation of BPs have been developed according to a evidence-based guideline and approved for clinical use in 2001 and in 2002, respectively. Although these BPs have been shown to have antifractures efficacy, great efforts have been made to explore convenient administration routes and schedules of BPs for individual patients. On the other hand, some of BPs are indicated for abnormal bone and calcium metabolism other than osteoporosis, including Paget's disease of bone, hypercalcemia associated with malignancy. Currently, extended indications of BPs are under development to the treatments of metastatic bone diseases, such as breast cancer, multiple myeloma, and rheumatoid arthritis. Since etidronate, first generation of BP also have the inhibitory effects on mineralization and hydroxyapatite crystal formation, application of this agent to ectopic ossification and calcification are very promising and under investigation.

Links

Aggregator Full Text

Authors+Show Affiliations

Nakatsuka K
Department of Endocrinology, Metabolism, and Molecular Medicine, Osaka City University Graduate School of Medicine.

MeSH

Bone ResorptionDiphosphonatesHumansHypercalcemiaOsteitis DeformansOsteoporosis

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

12638211

Citation

Nakatsuka, Kiyoshi. "[Development of Bisphosphonates]." Nihon Rinsho. Japanese Journal of Clinical Medicine, vol. 61, no. 2, 2003, pp. 219-25.
Nakatsuka K. [Development of bisphosphonates]. Nihon Rinsho. 2003;61(2):219-25.
Nakatsuka, K. (2003). [Development of bisphosphonates]. Nihon Rinsho. Japanese Journal of Clinical Medicine, 61(2), 219-25.
Nakatsuka K. [Development of Bisphosphonates]. Nihon Rinsho. 2003;61(2):219-25. PubMed PMID: 12638211.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Development of bisphosphonates]. A1 - Nakatsuka,Kiyoshi, PY - 2003/3/18/pubmed PY - 2003/4/26/medline PY - 2003/3/18/entrez SP - 219 EP - 25 JF - Nihon rinsho. Japanese journal of clinical medicine JO - Nihon Rinsho VL - 61 IS - 2 N2 - Bisphosphonates (BPs), antiresorptive agents, have been established as first line drugs for treatment of osteoporosis and widely used all over the worlds. In Japan alendronate and risedronate, newer generation of BPs have been developed according to a evidence-based guideline and approved for clinical use in 2001 and in 2002, respectively. Although these BPs have been shown to have antifractures efficacy, great efforts have been made to explore convenient administration routes and schedules of BPs for individual patients. On the other hand, some of BPs are indicated for abnormal bone and calcium metabolism other than osteoporosis, including Paget's disease of bone, hypercalcemia associated with malignancy. Currently, extended indications of BPs are under development to the treatments of metastatic bone diseases, such as breast cancer, multiple myeloma, and rheumatoid arthritis. Since etidronate, first generation of BP also have the inhibitory effects on mineralization and hydroxyapatite crystal formation, application of this agent to ectopic ossification and calcification are very promising and under investigation. SN - 0047-1852 UR - https://www.unboundmedicine.com/medline/citation/12638211/[Development_of_bisphosphonates]_ L2 - https://www.medicalonline.jp/meteo_linkout.php?issn=0047-1852&volume=61&issue=2&spage=219 DB - PRIME DP - Unbound Medicine ER -